Kenvue (NYSE:KVUE - Get Free Report) had its target price lifted by stock analysts at Barclays from $21.00 to $23.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Barclays's price target would indicate a potential downside of 3.14% from the stock's previous close.
A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Kenvue has an average rating of "Hold" and an average price target of $24.00.
Check Out Our Latest Stock Report on KVUE
Kenvue Stock Up 0.2 %
NYSE KVUE traded up $0.05 during trading hours on Thursday, hitting $23.75. 5,879,730 shares of the company were exchanged, compared to its average volume of 16,703,482. The company has a 50 day moving average of $22.32 and a two-hundred day moving average of $22.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $45.38 billion, a price-to-earnings ratio of 44.76, a PEG ratio of 2.62 and a beta of 1.25. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Alerus Financial NA boosted its stake in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock worth $4,426,000 after buying an additional 491 shares during the period. Kiley Juergens Wealth Management LLC lifted its position in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after acquiring an additional 500 shares during the period. Principle Wealth Partners LLC grew its stake in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC increased its holdings in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after purchasing an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its holdings in shares of Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after purchasing an additional 568 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
